|
ES2390425T3
(es)
|
2000-12-22 |
2012-11-12 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Uso de moléculas de orientación repulsivas (RGM) y sus moduladores
|
|
EP1228766A1
(en)
*
|
2001-01-31 |
2002-08-07 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
PYK2 phosphorylation by HER3 induces tumor invasion
|
|
US8505468B2
(en)
*
|
2002-11-19 |
2013-08-13 |
Sharp Kabushiki Kaisha |
Substrate accommodating tray
|
|
US8759490B2
(en)
|
2005-03-24 |
2014-06-24 |
Millennium Pharamaceuticals, Inc. |
Antibodies that bind OV064 and methods of use therefor
|
|
US8323645B2
(en)
*
|
2005-03-24 |
2012-12-04 |
Millennium Pharmaceuticals, Inc. |
Antibodies that bind OV064 and methods of use therefor
|
|
CN101277974A
(zh)
|
2005-09-30 |
2008-10-01 |
阿伯特有限及两合公司 |
排斥性引导分子(rgm)蛋白质家族的蛋白质的结合结构域及其功能性片段和它们的用途
|
|
AU2015201263B2
(en)
*
|
2005-12-30 |
2017-01-12 |
Amgen Inc. |
Material and methods for treating or preventing her-3 associated diseases
|
|
AR056857A1
(es)
|
2005-12-30 |
2007-10-24 |
U3 Pharma Ag |
Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
|
|
EP2518508A1
(en)
|
2006-11-28 |
2012-10-31 |
U3 Pharma GmbH |
Activated HER3 as a marker for predicting therapeutic efficacy
|
|
SG178789A1
(en)
*
|
2007-02-16 |
2012-03-29 |
Merrimack Pharmaceuticals Inc |
Antibodies against erbb3 and uses thereof
|
|
BRPI0809435A2
(pt)
|
2007-03-27 |
2014-09-09 |
Sea Lane Biotechnologies, Llc |
Constructos e bibliotecas que compreendem sequências de cadeia leve substituida de anticorpos
|
|
EP1997830A1
(en)
|
2007-06-01 |
2008-12-03 |
AIMM Therapeutics B.V. |
RSV specific binding molecules and means for producing them
|
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
|
JP5646457B2
(ja)
|
2008-04-29 |
2014-12-24 |
アッヴィ・インコーポレイテッド |
二重可変ドメイン免疫グロブリン及びその使用
|
|
BRPI0911451A2
(pt)
*
|
2008-05-25 |
2019-09-24 |
Wyeth Llc |
biomarcadores para eficácia medicamentosa de egfr/her/erb
|
|
PE20100054A1
(es)
|
2008-06-03 |
2010-03-03 |
Abbott Lab |
Inmunoglobulina con dominio variable dual
|
|
EP2138511A1
(en)
*
|
2008-06-27 |
2009-12-30 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
HER3 as a determinant for the prognosis of melanoma
|
|
MX2010014574A
(es)
|
2008-07-08 |
2011-04-27 |
Abbott Lab |
Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
|
|
AU2013202410B2
(en)
*
|
2008-07-16 |
2014-10-09 |
Institute For Research In Biomedicine |
Human cytomegalovirus neautralizing antibodies and use thereof
|
|
WO2010019952A2
(en)
*
|
2008-08-15 |
2010-02-18 |
Merrimack Pharmaceuticals, Inc. |
Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted response
|
|
AU2009308707A1
(en)
*
|
2008-10-31 |
2010-05-06 |
Biogen Idec Ma Inc. |
LIGHT targeting molecules and uses thereof
|
|
WO2010085845A1
(en)
*
|
2009-01-28 |
2010-08-05 |
The University Of Queensland |
Cancer therapy and/or diagnosis
|
|
WO2010097186A1
(en)
*
|
2009-02-24 |
2010-09-02 |
Roche Diagnostic Gmbh |
Use of s-erbb-3 as a marker for cancer
|
|
SG10201402742YA
(en)
|
2009-03-20 |
2014-08-28 |
Genentech Inc |
Bispecific anti-her antibodies
|
|
JP5587975B2
(ja)
|
2009-04-07 |
2014-09-10 |
ロシュ グリクアート アクチェンゲゼルシャフト |
二重特異的抗−ＥｒｂＢ−３／抗−ｃ−Ｍｅｔ抗体
|
|
WO2010127181A1
(en)
|
2009-04-29 |
2010-11-04 |
Trellis Bioscience, Inc. |
Improved antibodies immunoreactive with heregulin-coupled her3
|
|
JP2012526839A
(ja)
|
2009-05-13 |
2012-11-01 |
シー レーン バイオテクノロジーズ， エルエルシー |
インフルエンザウイルスに対する中和分子
|
|
WO2011004899A1
(en)
*
|
2009-07-06 |
2011-01-13 |
Takeda Pharmaceutical Company Limited |
Cancerous disease modifying antibodies
|
|
AR078254A1
(es)
|
2009-09-01 |
2011-10-26 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
JP2013507378A
(ja)
*
|
2009-10-09 |
2013-03-04 |
メルク・シャープ・エンド・ドーム・コーポレイション |
抗ｈｅｒ３抗体の製造、特徴づけ及びその用途
|
|
MX2012004415A
(es)
|
2009-10-15 |
2012-05-08 |
Abbott Lab |
Inmunoglobulinas de dominio variable doble y usos de las mismas.
|
|
MX366890B
(es)
*
|
2009-10-23 |
2019-07-30 |
Millennium Pharm Inc |
Moléculas de anticuerpo anti - gcc y composiciones y métodos relacionados.
|
|
UY32979A
(es)
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
ES2860453T3
(es)
|
2009-10-30 |
2021-10-05 |
Novartis Ag |
Bibliotecas universales del dominio de unión del lado inferior de la fibronectina de tipo III
|
|
BR112012012160B1
(pt)
*
|
2009-11-13 |
2022-04-26 |
Amgen, Inc. |
Material e métodos para tratar ou prevenir doenças associadas ao her-3
|
|
KR20120118002A
(ko)
|
2009-12-08 |
2012-10-25 |
애보트 게엠베하 운트 콤파니 카게 |
망막 신경 섬유 층 변성의 치료에 사용하기 위한 ｒｇｍ ａ 단백질에 대한 모노클로날 항체
|
|
PH12012501157A1
(en)
*
|
2009-12-22 |
2012-10-29 |
Roche Glycart Ag |
Anti-her3 antibodies and uses thereof
|
|
EP2543727B1
(en)
|
2010-03-02 |
2016-08-31 |
Kyowa Hakko Kirin Co., Ltd. |
Modified antibody composition
|
|
KR101798679B1
(ko)
|
2010-03-11 |
2017-11-16 |
메리맥 파마슈티컬즈, 인크. |
３중 음성 및 기저형 유방암 치료 시의 ｅｒｂｂ３ 저해제의 용도
|
|
US8481687B2
(en)
*
|
2010-04-09 |
2013-07-09 |
Aveo Pharmaceuticals, Inc. |
Anti-ErbB3 antibodies
|
|
MX2012013490A
(es)
|
2010-05-20 |
2013-01-29 |
Ablynx Nv |
Materiales biologicos relacionados con her3.
|
|
PH12013500064A1
(en)
|
2010-07-09 |
2013-03-11 |
Exelixis Inc |
Combinations of kinase inhibitors for the treatment of cancer
|
|
MX345300B
(es)
|
2010-07-30 |
2017-01-24 |
Novartis Ag * |
Moléculas andamio de fibronectina y bibliotecas de las mismas.
|
|
US8735546B2
(en)
|
2010-08-03 |
2014-05-27 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
|
WO2012019024A2
(en)
*
|
2010-08-04 |
2012-02-09 |
Immunogen, Inc. |
Her3-binding molecules and immunoconjugates thereof
|
|
CA2815154A1
(en)
*
|
2010-08-06 |
2012-02-09 |
U3 Pharma Gmbh |
Use of her3 binding agents in prostate treatment
|
|
SG187908A1
(en)
*
|
2010-08-20 |
2013-03-28 |
Novartis Ag |
Antibodies for epidermal growth factor receptor 3 (her3)
|
|
PH12013500337A1
(en)
|
2010-08-26 |
2017-08-23 |
Abbvie Inc |
Dual variable domain immunoglobulins and uses thereof
|
|
TW201302793A
(zh)
*
|
2010-09-03 |
2013-01-16 |
Glaxo Group Ltd |
新穎之抗原結合蛋白
|
|
IT1402149B1
(it)
*
|
2010-10-04 |
2013-08-28 |
Ist Fisioterap Ospitalroma |
Uso di un fosfopeptide in grado di bloccare l interazione her3/p85 per il trattamento dei tumori iperesprimenti her2.
|
|
AU2011317743B2
(en)
*
|
2010-10-18 |
2015-05-21 |
Mediapharma S.R.L. |
ErbB3 binding antibody
|
|
KR101862832B1
(ko)
*
|
2010-11-01 |
2018-05-30 |
심포젠 에이/에스 |
Ｐａｎ―ｈｅｒ 항체 조성물
|
|
US9155802B2
(en)
|
2010-11-01 |
2015-10-13 |
Symphogen A/S |
Pan-HER antibody composition
|
|
ITRM20100577A1
(it)
*
|
2010-11-02 |
2012-05-03 |
Takis Srl |
Immunoterapia contro il recettore erbb-3
|
|
PT2653540T
(pt)
|
2010-12-15 |
2018-02-27 |
Kyowa Hakko Kirin Co Ltd |
Processo de produção de proteínas
|
|
CA2823337C
(en)
*
|
2010-12-29 |
2019-09-10 |
Expression Pathology, Inc. |
Her3 protein srm/mrm assay
|
|
BR112013022882A2
(pt)
|
2011-03-11 |
2016-12-20 |
Merrimack Pharmaceuticals Inc |
uso de inibidores de receptores da família egfr no tratamento de cânceres de mama hormônio-refratários
|
|
JP2014509593A
(ja)
|
2011-03-15 |
2014-04-21 |
メリマック ファーマシューティカルズ インコーポレーティッド |
ＥｒｂＢ経路阻害剤に対する耐性の克服
|
|
UA117218C2
(uk)
|
2011-05-05 |
2018-07-10 |
Мерк Патент Гмбх |
Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
|
|
US9346883B2
(en)
|
2011-05-13 |
2016-05-24 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Antibodies against HER3
|
|
JP2014516960A
(ja)
*
|
2011-05-19 |
2014-07-17 |
インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） |
抗ヒトｈｅｒ３抗体及びその使用
|
|
KR20140033152A
(ko)
*
|
2011-06-20 |
2014-03-17 |
교와 핫꼬 기린 가부시키가이샤 |
항erbB3 항체
|
|
EP2736928B1
(en)
|
2011-07-28 |
2019-01-09 |
i2 Pharmaceuticals, Inc. |
Sur-binding proteins against erbb3
|
|
CN103857700A
(zh)
|
2011-08-26 |
2014-06-11 |
梅里麦克制药股份有限公司 |
串联fc双特异性抗体
|
|
US9273143B2
(en)
|
2011-09-30 |
2016-03-01 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
|
|
PH12014500483A1
(en)
*
|
2011-09-30 |
2014-04-14 |
Regeneron Pharma |
Anti-erbb3 antibodies and uses thereof
|
|
AU2012318541B2
(en)
|
2011-10-06 |
2018-04-12 |
Aveo Pharmaceuticals, Inc. |
Predicting tumor response to anti-ERBB3 antibodies
|
|
JP2015504038A
(ja)
|
2011-10-31 |
2015-02-05 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
低減した免疫原性を有するフィブロネクチン結合ドメイン
|
|
JP6149042B2
(ja)
*
|
2011-11-09 |
2017-06-14 |
ザ ユーエービー リサーチ ファンデーション |
Ｈｅｒ３抗体およびその使用
|
|
MX350957B
(es)
|
2011-11-23 |
2017-09-27 |
Medimmune Llc |
Moleculas de union especificas para her3 y usos de las mismas.
|
|
TW201331225A
(zh)
*
|
2011-12-05 |
2013-08-01 |
Novartis Ag |
針對表皮生長因子受體３（ｈｅｒ３）之域ｉｉｉ及域ｉｖ之ｈｅｒ３抗體
|
|
JP2015500829A
(ja)
*
|
2011-12-05 |
2015-01-08 |
ノバルティス アーゲー |
上皮細胞増殖因子受容体３（ｈｅｒ３）のドメインｉｉに対するｈｅｒ３の抗体
|
|
KR102083957B1
(ko)
|
2011-12-05 |
2020-03-04 |
노파르티스 아게 |
표피 성장 인자 수용체 3 (her3)에 대한 항체
|
|
EP2793940B1
(en)
|
2011-12-22 |
2018-11-14 |
i2 Pharmaceuticals, Inc. |
Surrogate binding proteins
|
|
US9120870B2
(en)
|
2011-12-30 |
2015-09-01 |
Abbvie Inc. |
Dual specific binding proteins directed against IL-13 and IL-17
|
|
EP3369746A1
(en)
|
2012-01-27 |
2018-09-05 |
AbbVie Deutschland GmbH & Co KG |
Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
|
|
CN108404129A
(zh)
|
2012-02-23 |
2018-08-17 |
第三共欧洲有限公司 |
用于调节放射敏感性的her3抑制剂
|
|
RU2014136886A
(ru)
|
2012-03-27 |
2016-05-20 |
Дженентек, Инк. |
Диагностика и виды лечения, связанные с ингибиторами her3
|
|
CA2871614C
(en)
|
2012-04-27 |
2021-08-31 |
Millennium Pharmaceuticals, Inc. |
Anti-gcc antibody molecules and use of same to test for susceptibility to gcc-targeted therapy
|
|
HK1202431A1
(en)
|
2012-05-02 |
2015-10-02 |
Symphogen A/S |
Humanized pan-her antibody compositions
|
|
HK1215950A1
(zh)
|
2012-09-25 |
2016-09-30 |
艾科诺斯科技股份有限公司 |
异源二聚免疫球蛋白的纯化
|
|
CA2928539A1
(en)
|
2012-10-25 |
2014-05-01 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind erbb3
|
|
AU2013337775B2
(en)
|
2012-11-01 |
2017-03-30 |
Abbvie Inc. |
Anti-VEGF/DLL4 dual variable domain immunoglobulins and uses thereof
|
|
US9725511B2
(en)
|
2012-11-08 |
2017-08-08 |
Hoffmann-La Roche Inc. |
Anti-HER3/HER4 antibodies binding to the beta-hairpin of HER3 and the beta-hairpin of HER4
|
|
WO2014072306A1
(en)
|
2012-11-08 |
2014-05-15 |
F. Hoffmann-La Roche Ag |
Her3 antigen binding proteins binding to the beta-hairpin of her3
|
|
UY35148A
(es)
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
Immunoglobulinas heterodiméricas
|
|
AR094403A1
(es)
|
2013-01-11 |
2015-07-29 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos anti-her3
|
|
CA2902505A1
(en)
|
2013-03-06 |
2014-09-12 |
Merrimack Pharmaceuticals, Inc. |
Anti-c-met tandem fc bispecific antibodies
|
|
AU2014239903A1
(en)
|
2013-03-14 |
2015-09-17 |
Genentech, Inc. |
Combinations of a MEK inhibitor compound with an HER3/EGFR inhibitor compound and methods of use
|
|
WO2014159915A1
(en)
*
|
2013-03-14 |
2014-10-02 |
The Board Of Regents Of The University Of Texas System |
Her3 specific monoclonal antibodies for diagnostic and therapeutic use
|
|
WO2014144817A2
(en)
|
2013-03-15 |
2014-09-18 |
Amgen Inc. |
Inhibitory polypeptides specific to wnt inhibitors
|
|
EP2970459A2
(en)
|
2013-03-15 |
2016-01-20 |
AbbVie Inc. |
Dual specific binding proteins directed against il-1beta and il-17
|
|
EP2821071A1
(en)
|
2013-07-04 |
2015-01-07 |
Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) |
Compounds for breast cancer treatment
|
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
|
CA2923145C
(en)
|
2013-09-05 |
2025-09-16 |
Amgen Inc. |
MOLECULES CONTAINING FCS AND EXHIBITING PREDICTABLE, UNIFORM AND REPRODUCIBLE GLYCOFORM PROFILES
|
|
WO2015048008A2
(en)
|
2013-09-24 |
2015-04-02 |
Medimmune, Llc |
Binding molecules specific for her3 and uses thereof
|
|
WO2015066543A1
(en)
*
|
2013-11-01 |
2015-05-07 |
Board Of Regents, The University Of Texas System |
Targeting her2 and her3 with bispecific antibodies in cancerous cells
|
|
CA2929386C
(en)
|
2013-11-07 |
2023-01-03 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Neuregulin allosteric anti-her3 antibody
|
|
EP3087394A2
(en)
|
2013-12-27 |
2016-11-02 |
Merrimack Pharmaceuticals, Inc. |
Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
|
|
MY178160A
(en)
|
2014-03-11 |
2020-10-06 |
Regeneron Pharma |
Anti-egfrviii antibodies and uses thereof
|
|
CN111228511B
(zh)
|
2014-04-10 |
2024-06-18 |
第一三共株式会社 |
抗her3抗体-药物偶联物
|
|
US10745490B2
(en)
|
2014-04-11 |
2020-08-18 |
Celldex Therapeutics, Inc. |
Anti-ErbB antibodies and methods of use thereof
|
|
FR3020063A1
(fr)
|
2014-04-16 |
2015-10-23 |
Gamamabs Pharma |
Anticorps humain anti-her4
|
|
EP3143048B1
(en)
|
2014-05-14 |
2019-08-28 |
F. Hoffmann-La Roche AG |
Anti-her3 antibodies binding to the beta-hairpin of her3
|
|
MX377275B
(es)
|
2014-05-16 |
2025-03-07 |
Amgen Inc |
Ensayo para detectar poblaciones celulares linfocitos t colaboradores 1 (th1) y linfocitos t colaboradores (th2).
|
|
WO2016059602A2
(en)
|
2014-10-16 |
2016-04-21 |
Glaxo Group Limited |
Methods of treating cancer and related compositions
|
|
US10093733B2
(en)
|
2014-12-11 |
2018-10-09 |
Abbvie Inc. |
LRP-8 binding dual variable domain immunoglobulin proteins
|
|
WO2016145099A1
(en)
|
2015-03-09 |
2016-09-15 |
Agensys, Inc. |
Antibody drug conjugates (adc) that bind to flt3 proteins
|
|
EP3091033A1
(en)
|
2015-05-06 |
2016-11-09 |
Gamamabs Pharma |
Anti-human-her3 antibodies and uses thereof
|
|
US10184006B2
(en)
|
2015-06-04 |
2019-01-22 |
Merrimack Pharmaceuticals, Inc. |
Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
|
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
|
|
CN116059395A
(zh)
|
2015-06-29 |
2023-05-05 |
第一三共株式会社 |
用于选择性制造抗体-药物缀合物的方法
|
|
TW201716439A
(zh)
|
2015-07-20 |
2017-05-16 |
美國禮來大藥廠 |
Ｈｅｒ３抗體
|
|
US20220313841A1
(en)
*
|
2015-09-02 |
2022-10-06 |
Sanford Burnham Prebys Medical Discovery Institute |
Compositions and methods for treating nervous system injuries
|
|
CN108602890A
(zh)
|
2015-12-11 |
2018-09-28 |
瑞泽恩制药公司 |
用于减少或预防对egfr和/或erbb3阻滞剂具有抗性的肿瘤生长的方法
|
|
AU2017235450A1
(en)
|
2016-03-15 |
2018-08-16 |
Merrimack Pharmaceuticals, Inc. |
Methods for treating ER+, HER2-, HRG+ breast cancer using combination therapies comprising an anti-ErbB3 antibody
|
|
JP7145374B2
(ja)
*
|
2016-03-18 |
2022-10-03 |
ラトガース ザ ステイト ユニバーシティー オブ ニュージャージー |
インビボでの切断可能連結部分によって抗マトリプターゼ抗体にコンジュゲートされた化学療法剤を用いる腫瘍細胞の標的化
|
|
KR20190089034A
(ko)
|
2016-12-09 |
2019-07-29 |
시애틀 지네틱스, 인크. |
코일드 코일에 의해 차폐된 이가 항체
|
|
EP3552626A4
(en)
*
|
2016-12-12 |
2020-06-10 |
Daiichi Sankyo Company, Limited |
ASSOCIATION OF AN ANTIBODY DRUG CONJUGATE AND AN IMMUNE CONTROL POINT INHIBITOR
|
|
EP3572428A4
(en)
|
2017-01-17 |
2020-12-30 |
Daiichi Sankyo Company, Limited |
ANTI-BODY ANTI-GPR20 AND ANTI-BODY-DRUG CONJUGATE ANTI-GPR20
|
|
WO2018159582A1
(ja)
|
2017-02-28 |
2018-09-07 |
学校法人近畿大学 |
抗ｈｅｒ３抗体－薬物コンジュゲート投与によるｅｇｆｒ－ｔｋｉ抵抗性の非小細胞肺癌の治療方法
|
|
AU2018235928B2
(en)
|
2017-03-14 |
2023-09-21 |
Amgen Inc. |
Control of total afucosylated glycoforms of antibodies produced in cell culture
|
|
TWI855528B
(zh)
|
2017-05-15 |
2024-09-11 |
日商第一三共股份有限公司 |
抗體-藥物結合物之製造方法
|
|
KR20200044044A
(ko)
|
2017-08-23 |
2020-04-28 |
다이이찌 산쿄 가부시키가이샤 |
항체-약물 콘주게이트의 제제 및 그 동결 건조 방법
|
|
KR20250084239A
(ko)
|
2017-08-31 |
2025-06-10 |
다이이찌 산쿄 가부시키가이샤 |
항체-약물 콘주게이트의 개량 제조 방법
|
|
JP7248578B2
(ja)
|
2017-08-31 |
2023-03-29 |
第一三共株式会社 |
抗体－薬物コンジュゲートの新規製造方法
|
|
US11795221B2
(en)
|
2018-02-28 |
2023-10-24 |
WuXi Biologics Ireland Limited |
Monoclonal antibody against human LAG-3, method for preparing the same, and use thereof
|
|
EP3768317A4
(en)
|
2018-03-22 |
2021-12-22 |
Surface Oncology, Inc. |
ANTI-IL-27 ANTIBODIES AND USES THEREOF
|
|
CN119639849A
(zh)
|
2018-03-26 |
2025-03-18 |
美国安进公司 |
细胞培养物中产生的抗体的总去岩藻糖基化糖型
|
|
WO2019210144A1
(en)
*
|
2018-04-27 |
2019-10-31 |
Vanderbilt University |
Broadly neutralizing antibodies against hepatitis c virus
|
|
HRP20240756T1
(hr)
|
2018-05-18 |
2024-09-13 |
Daiichi Sankyo Co., Ltd. |
Anti-muc1-eksatekan antitijelo-lijek konjugat
|
|
BR112021001194A2
(pt)
|
2018-07-25 |
2021-04-27 |
Daiichi Sankyo Company, Limited |
métodos para produzir um conjugado anticorpo-fármaco e para produzir uma composição farmacêutica
|
|
TWI846717B
(zh)
|
2018-07-27 |
2024-07-01 |
日商第一三共股份有限公司 |
辨識抗體-藥物結合物之藥物部位的蛋白質
|
|
EP3831412A4
(en)
|
2018-07-31 |
2022-04-27 |
Daiichi Sankyo Company, Limited |
TREATMENT OF METASTATIC BRAIN TUMOR BY ADMINISTRATION OF AN ANTIBODY-DRUG CONJUGATE
|
|
TW202019487A
(zh)
|
2018-08-06 |
2020-06-01 |
日商第一三共股份有限公司 |
抗體-藥物結合物及微管蛋白抑制劑之組合
|
|
EP3842546A4
(en)
|
2018-08-23 |
2022-06-29 |
Daiichi Sankyo Company, Limited |
Sensitivity marker for antibody-drug conjugate
|
|
KR102871791B1
(ko)
|
2018-09-10 |
2025-10-15 |
미라티 테라퓨틱스, 인크. |
병용 요법
|
|
CN112912109A
(zh)
|
2018-09-20 |
2021-06-04 |
第一三共株式会社 |
通过施用抗her3抗体-药物缀合物治疗her3-突变的癌症
|
|
CN111289748A
(zh)
*
|
2018-12-08 |
2020-06-16 |
惠州市中大惠亚医院 |
ErbB3蛋白在制备膀胱癌无创诊断产品中的应用
|
|
SG11202106248XA
(en)
|
2018-12-11 |
2021-07-29 |
Daiichi Sankyo Co Ltd |
Combination of antibody-drug conjugate with parp inhibitor
|
|
CN113195538B
(zh)
*
|
2018-12-12 |
2023-03-14 |
上海药明生物技术有限公司 |
抗tim-3抗体及其用途
|
|
SG11202105161YA
(en)
*
|
2018-12-13 |
2021-06-29 |
Surface Oncology Inc |
Anti-il-27 antibodies and uses thereof
|
|
CA3124330A1
(en)
|
2018-12-21 |
2020-06-25 |
Daiichi Sankyo Company, Limited |
Combination of antibody-drug conjugate and kinase inhibitor
|
|
AU2020355251A1
(en)
|
2019-09-26 |
2022-04-21 |
Amgen Inc. |
Methods of producing antibody compositions
|
|
JP7716399B2
(ja)
*
|
2019-11-01 |
2025-07-31 |
ブイオーアール バイオファーマ インコーポレーテッド |
抗－ｃｄ４５抗体及びそのコンジュゲート
|
|
BR112022014278A2
(pt)
*
|
2020-01-24 |
2022-09-20 |
Regeneron Pharma |
Conjugados de composto proteico-antiviral
|
|
KR20210095781A
(ko)
|
2020-01-24 |
2021-08-03 |
주식회사 에이프릴바이오 |
항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
|
|
US11896619B2
(en)
*
|
2020-03-10 |
2024-02-13 |
Massachusetts Institute Of Technology |
Compositions and methods for immunotherapy of NPM1c-positive cancer
|
|
CN111282165B
(zh)
*
|
2020-03-18 |
2025-03-21 |
核工业总医院 |
放射治疗定位显影液及定位显影标记敷贴
|
|
WO2021247892A1
(en)
|
2020-06-04 |
2021-12-09 |
Amgen Inc. |
Assessment of cleaning procedures of a biotherapeutic manufacturing process
|
|
CN122011191A
(zh)
|
2020-10-14 |
2026-05-12 |
苏州盛迪亚生物医药有限公司 |
抗her3抗体和抗her3抗体药物偶联物及其医药用途
|
|
AU2021360897A1
(en)
|
2020-10-15 |
2023-05-25 |
Amgen Inc. |
Relative unpaired glycans in antibody production methods
|
|
KR20230106645A
(ko)
|
2020-11-11 |
2023-07-13 |
다이이찌 산쿄 가부시키가이샤 |
항체-약물 콘주게이트와 항 SIRPα 항체의 조합
|
|
KR20230128271A
(ko)
*
|
2020-11-20 |
2023-09-04 |
악티늄 파마슈티컬즈, 인코포레이티드 |
고형 암의 치료를 위한 her3 방사선면역요법
|
|
US12551584B1
(en)
|
2020-12-07 |
2026-02-17 |
Actinium Pharmaceuticals, Inc. |
Lewis Y radioimmunotherapy for the treatment of cancer
|
|
KR20230164128A
(ko)
|
2021-03-31 |
2023-12-01 |
디디바이오. 코포레이션 엘티디.,(상하이) |
기능성 항원 결합 단백질 선별을 위한 벡터 및 방법
|
|
CN117337195A
(zh)
|
2021-04-29 |
2024-01-02 |
上海汇连生物医药有限公司 |
抗体偶联药物的制备方法及应用
|
|
AR126089A1
(es)
|
2021-06-07 |
2023-09-13 |
Amgen Inc |
Uso de fucosidasa para controlar el nivel de afucosilación de proteínas glucosiladas
|
|
IL309337A
(en)
*
|
2021-06-15 |
2024-02-01 |
Beijing Sinotau Bio Pharmaceuticals Tech Co Ltd |
Anti-HER3 antibody, anti-HER3 antibody-drug conjugate and uses thereof
|
|
CN117881431A
(zh)
|
2021-08-24 |
2024-04-12 |
昆山新蕴达生物科技有限公司 |
一种由可断裂连接子偶联的抗体偶联药物
|
|
WO2023059607A1
(en)
|
2021-10-05 |
2023-04-13 |
Amgen Inc. |
Fc-gamma receptor ii binding and glycan content
|
|
WO2023103854A1
(zh)
|
2021-12-09 |
2023-06-15 |
昆山新蕴达生物科技有限公司 |
一种亲和力改善的抗体-药物偶联物、其制备方法及应用
|
|
IL314567A
(en)
|
2022-01-28 |
2024-09-01 |
Duality Biologics Suzhou Co Ltd |
Drug-conjugated antibody to HER3 and its use
|
|
KR20240153994A
(ko)
*
|
2022-03-03 |
2024-10-24 |
쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 |
Her3 결합 단백질 및 그의 용도
|
|
WO2023209591A1
(en)
|
2022-04-27 |
2023-11-02 |
Daiichi Sankyo Company, Limited |
Combination of antibody-drug conjugate with ezh1 and/or ezh2 inhibitor
|
|
US20250281631A1
(en)
*
|
2022-04-29 |
2025-09-11 |
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd |
Antibody-drug conjugates and preparation methods and use thereof
|
|
WO2023215725A1
(en)
|
2022-05-02 |
2023-11-09 |
Fred Hutchinson Cancer Center |
Compositions and methods for cellular immunotherapy
|
|
TW202400650A
(zh)
|
2022-05-11 |
2024-01-01 |
日商第一三共股份有限公司 |
抗體與cd47抑制劑之組合
|
|
IL322569A
(en)
|
2023-02-09 |
2025-10-01 |
Beone Medicines I Gmbh |
Self-stabilizing bonding material bracelets
|
|
AU2024256160A1
(en)
|
2023-04-20 |
2025-10-02 |
Amgen Inc. |
Methods of determining relative unpaired glycan content
|
|
CN121219016A
(zh)
|
2023-06-02 |
2025-12-26 |
第一三共株式会社 |
抗-her3抗体-药物缀合物和rasg12c抑制剂的组合
|
|
CN116444672B
(zh)
|
2023-06-13 |
2023-11-03 |
上海偌妥生物科技有限公司 |
人表皮生长因子3的抗体、其制备方法及其应用
|
|
CN121568721A
(zh)
|
2023-06-29 |
2026-02-24 |
广州百济神州生物制药有限公司 |
生物活性缀合物、其制备方法和其用途
|
|
EP4735049A1
(en)
|
2023-06-29 |
2026-05-06 |
Beone Medicines I GmbH |
Bioactive conjugates, preparation method and use thereof
|
|
WO2025005240A1
(ja)
|
2023-06-30 |
2025-01-02 |
第一三共株式会社 |
活性炭材料を使用する精製工程を含む抗体－薬物コンジュゲートの製造方法
|
|
AU2024325342A1
(en)
|
2023-08-14 |
2026-02-26 |
Amgen Inc. |
Methods for reducing yellow color
|
|
WO2025101820A1
(en)
|
2023-11-08 |
2025-05-15 |
Fred Hutchinson Cancer Center |
Compositions and methods for cellular immunotherapy
|
|
TW202540193A
(zh)
*
|
2024-03-14 |
2025-10-16 |
大陸商珠海普米斯生物科技有限公司 |
雙特異性抗體、抗體藥物偶聯物及其應用
|
|
WO2026090253A1
(en)
|
2024-10-23 |
2026-04-30 |
Amgen Inc. |
Methods of determining glycan pairing content
|